Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract 5252: Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib

Heiko Krissel, Andrea Hennig, Danny Zhang, Rodrigo Ito, Christine Gonschorek, Fabricio Souza, Martina Poethig, Kathleen Schostack, Joachim Reischl, Philipp Angenendt, Barrett H. Childs, Michael Teufel

Cancer Res (2015) 75 (15_Supplement): 5252.

https://doi.org/10.1158/1538-7445.AM2015-5252

Published: 01 August 2015

View article titled, Abstract 5252: Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib

Journal Articles

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Cancer Res (2012) 72 (4): 969–978.

https://doi.org/10.1158/0008-5472.CAN-11-1875

Published: 14 February 2012

View article titled, Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Includes: Supplementary data

Journal Articles

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su

Cancer Res (2012) 72 (3): 779–789.

https://doi.org/10.1158/0008-5472.CAN-11-2941

Published: 31 January 2012

View article titled, Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Includes: Supplementary data

Journal Articles

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAF^V600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

Brian Higgins, Kenneth Kolinksy, Zenaida Go, Hing Char, Richard Lee, Kathleen Schostack, Gideon Bollag, David Heimbrook, Fei Su, Kathryn E. Packman

Cancer Res (2011) 71 (8_Supplement): 2562.

https://doi.org/10.1158/1538-7445.AM2011-2562

Published: 15 April 2011

View article titled, Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

Journal Articles

RG7204 (PLX4032), a Selective BRAF^V600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley Kolis, Sylvia Zhao, Richard Lee, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su

Cancer Res (2010) 70 (13): 5518–5527.

https://doi.org/10.1158/0008-5472.CAN-10-0646

Published: 30 June 2010

View article titled, RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Includes: Supplementary data

Journal Articles

Abstract #4420: PLX4032, a selective B-Raf^V600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Fei Su, Hong Yang, Brian Higgins, Kenneth Kolinsky, Richard Lee, Kathryn Packman, Kathleen Schostack, David Heimbrook, Gideon Bollag

Cancer Res (2009) 69 (9_Supplement): 4420.

Published: 01 May 2009

View article titled, Abstract #4420: PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

NARROW

Abstract 5252: Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAF^V600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

RG7204 (PLX4032), a Selective BRAF^V600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Abstract #4420: PLX4032, a selective B-Raf^V600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Email alerts

AACR Journals

Abstract 5252: Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAFV600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Abstract #4420: PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Abstract 2562: Efficacy of RG7204 (PLX4032), a selective BRAF^V600E inhibitor, in combination with pegylated interferon alpha-2a (Pegasys), paclitaxel, carboplatin, and anti-VEGF MAb B20-4.1 in the LOX-IMVI human melanoma xenograft model

RG7204 (PLX4032), a Selective BRAF^V600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Abstract #4420: PLX4032, a selective B-Raf^V600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models